Theriva Biologics, Inc.

NYSE:TOVX

Pharmaceutical Preparations·ROCKVILLE, MD

CEO

Shallcross Steven A

Financials

20 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/12/25	→
10-Q	Q2 2025	6/30/25	8/11/25	→
10-Q	Q1 2025	3/31/25	5/14/25	→
10-K	FY 2024	12/31/24	3/6/25	→
10-Q	Q3 2024	9/30/24	11/12/24	→
10-Q	Q2 2024	6/30/24	8/13/24	→
↓

Earnings Releases (8-K)

15 shown

Filed	Period
11/12/25	Q4 FY2025	→
8/11/25	Q3 FY2025	→
5/14/25	Q2 FY2025	→
3/6/25	Q1 FY2025	→
11/12/24	Q4 FY2024	→
8/13/24	Q3 FY2024	→
↓

News (8-K)

65 shown

Filed	Type	Description
2/18/26	Agreement	Entry into a Material Definitive Agreement	→
2/12/26	Other	Other Events	→
1/12/26	Other	Other Events	→
12/29/25	Reg FD	Regulation FD Disclosure	→
12/15/25	Other	Other Events	→
10/29/25	Other	Other Events	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
12/3/25	424B5	424B5	→
11/7/25	S-3	S-3	→
10/29/25	424B5	424B5	→
10/24/25	424B5	424B5	→
10/16/25	424B5	424B5	→
10/16/25	424B5	424B5	→
↓

Filing History(1000 filings)

TypeDateAccessionPeriodSize

PRE 14A

Mar 4, 2026

0001104659-26-023448PRE 14A

Mar 4, 2026

763.4 KB

8-K

Feb 18, 2026

0001104659-26-016792FORM 8-K

Feb 17, 2026

661.2 KB

8-K

Feb 12, 2026

0001104659-26-013907FORM 8-K

Feb 11, 2026

185.8 KB

8-K

Jan 12, 2026

0001104659-26-002750FORM 8-K

Jan 12, 2026

12.1 MB

Jan 6, 2026

0001104659-26-001388OWNERSHIP DOCUMENT

Jan 5, 2026

5.9 KB

Jan 6, 2026

0001104659-26-001384OWNERSHIP DOCUMENT

Jan 5, 2026

5.6 KB

Jan 6, 2026

0001104659-26-001383OWNERSHIP DOCUMENT

Jan 5, 2026

5.6 KB

Jan 6, 2026

0001104659-26-001381OWNERSHIP DOCUMENT

Jan 5, 2026

5.7 KB

DEF 14A

Jan 5, 2026

0001104659-26-000633DEF 14A

Feb 11, 2026

425.3 KB

8-K

Dec 29, 2025

0001104659-25-124523FORM 8-K

Dec 29, 2025

228.3 KB

PRE 14A

Dec 23, 2025

0001104659-25-124168PRE 14A

Dec 23, 2025

413.5 KB

8-K

Dec 15, 2025

0001104659-25-121246FORM 8-K

Dec 15, 2025

186.1 KB

424B5

Dec 3, 2025

0001104659-25-118116424B5

—

228.1 KB

EFFECT

Dec 2, 2025

9999999995-25-003480

—

2.0 KB

DEFA14A

Nov 12, 2025

0001104659-25-110362DEFA14A

—

307.1 KB

10-Q

Nov 12, 2025

0001104659-25-10982810-Q

Sep 30, 2025

7.4 MB

8-K

Nov 12, 2025

0001104659-25-109821FORM 8-K

Nov 12, 2025

324.8 KB

SCHEDULE 13G

Nov 10, 2025

0002096075-25-000001

—

159.9 KB

DEF 14A

Nov 10, 2025

0001104659-25-109200DEF 14A

Dec 15, 2025

422.6 KB

S-3

Nov 7, 2025

0001104659-25-108521S-3

—

466.5 KB

PRE 14A

Oct 31, 2025

0001104659-25-104926PRE 14A

Dec 15, 2025

423.1 KB

8-K

Oct 29, 2025

0001104659-25-103774FORM 8-K

Oct 29, 2025

218.6 KB

424B5

Oct 29, 2025

0001104659-25-103770424B5

—

829.1 KB

8-K

Oct 24, 2025

0001104659-25-102104FORM 8-K

Oct 24, 2025

210.9 KB

424B5

Oct 24, 2025

0001104659-25-102103424B5

—

628.8 KB

25 filings shown

Theriva Biologics, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(1000 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/4/26	PRE 14A	PRE 14A	→
1/5/26	DEF 14A	DEF 14A	→
12/23/25	PRE 14A	PRE 14A	→
11/12/25	DEFA14A	DEFA14A	→
11/10/25	DEF 14A	DEF 14A	→
10/31/25	PRE 14A	PRE 14A	→
↓

Filed	Form	Description
1/6/26	4	OWNERSHIP DOCUMENT	→
1/6/26	4	OWNERSHIP DOCUMENT	→
1/6/26	4	OWNERSHIP DOCUMENT	→
1/6/26	4	OWNERSHIP DOCUMENT	→
5/1/25	4	OWNERSHIP DOCUMENT	→
5/1/25	4	OWNERSHIP DOCUMENT	→
↓

Filed	Form	Description
12/2/25	EFFECT	EFFECT	→
11/10/25	SCHEDULE 13G	SCHEDULE 13G	→
10/24/25	D	D	→
10/21/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
7/31/25	SCHEDULE 13G	SCHEDULE 13G	→
5/7/25	EFFECT	EFFECT	→
↓